Calithera Biosciences (NASDAQ:CALA) Stock Price Down 15%

Shares of Calithera Biosciences Inc (NASDAQ:CALA) traded down 15% during trading on Monday . The stock traded as low as $3.45 and last traded at $3.56, 558,797 shares changed hands during mid-day trading. An increase of 107% from the average session volume of 270,466 shares. The stock had previously closed at $4.19.

Several analysts recently commented on the stock. ValuEngine upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday. Citigroup restated a “buy” rating and set a $10.00 price objective on shares of Calithera Biosciences in a research report on Thursday, May 30th. Finally, William Blair restated a “buy” rating on shares of Calithera Biosciences in a research report on Friday, June 21st.

The stock has a market cap of $139.70 million, a P/E ratio of -2.39 and a beta of 1.86. The company has a current ratio of 6.75, a quick ratio of 6.75 and a debt-to-equity ratio of 0.08. The stock has a 50-day simple moving average of $4.19.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.18). As a group, equities research analysts forecast that Calithera Biosciences Inc will post -2.06 EPS for the current fiscal year.

In related news, insider Susan Molineaux purchased 51,600 shares of the stock in a transaction dated Tuesday, June 25th. The shares were acquired at an average cost of $3.88 per share, with a total value of $200,208.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 17.20% of the company’s stock.

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Calithera Biosciences in the 2nd quarter worth approximately $112,000. Federated Investors Inc. PA lifted its holdings in Calithera Biosciences by 6.2% in the 1st quarter. Federated Investors Inc. PA now owns 3,767,763 shares of the biotechnology company’s stock worth $25,395,000 after purchasing an additional 218,869 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Calithera Biosciences by 378.5% in the 1st quarter. Acadian Asset Management LLC now owns 57,114 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 45,177 shares during the last quarter. Rhumbline Advisers lifted its holdings in Calithera Biosciences by 4.1% in the 1st quarter. Rhumbline Advisers now owns 47,201 shares of the biotechnology company’s stock worth $318,000 after purchasing an additional 1,869 shares during the last quarter. Finally, Alps Advisors Inc. lifted its holdings in Calithera Biosciences by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 92,089 shares of the biotechnology company’s stock worth $621,000 after purchasing an additional 3,977 shares during the last quarter. 56.78% of the stock is currently owned by institutional investors and hedge funds.

Calithera Biosciences Company Profile (NASDAQ:CALA)

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Recommended Story: Return on Equity (ROE)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.